Title:
ANTI-CTLA-4 ANTIBODY AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2022/184155
Kind Code:
A1
Abstract:
The present invention relates to the technical field of antibody drugs, in particular to an anti-CTLA-4 antibody or an antigen-binding fragment thereof, an anti-CTLA-4/anti-PD-1 antibody or an antigen-binding fragment thereof, a pharmaceutical composition containing the anti-CTLA-4 antibody or the antigen-binding fragment thereof or the anti-CTLA-4/anti-PD-1 antibody or the antigen-binding fragment thereof, and the use thereof. The anti-CTLA-4 antibody and the anti-CTLA-4/anti-PD-1 antibody of the present invention have a significant anti-tumor activity and can be used in the preparation of anti-tumor drugs.
Inventors:
XIAO YANG (CN)
LI XUE (CN)
ZHOU XINRAN (CN)
ZHAO LIWEN (CN)
LI XUE (CN)
ZHOU XINRAN (CN)
ZHAO LIWEN (CN)
Application Number:
PCT/CN2022/079170
Publication Date:
September 09, 2022
Filing Date:
March 04, 2022
Export Citation:
Assignee:
NANJING SANHOME PHARMACEUTICAL CO LTD (CN)
International Classes:
C07K16/28; A61K39/395; A61P35/00; C07K16/46; C12N15/13
Domestic Patent References:
| WO2019179391A1 | 2019-09-26 |
Foreign References:
| CN108948194A | 2018-12-07 | |||
| CN104974253A | 2015-10-14 | |||
| CN104987421A | 2015-10-21 | |||
| CN105754990A | 2016-07-13 | |||
| CN108367069A | 2018-08-03 | |||
| CN110343180A | 2019-10-18 |
Attorney, Agent or Firm:
NANJING TIANHUA PATENT AGENT CO., LTD. (CN)
Download PDF: